Novo Nordisk Receives EU Approval for Higher-Dose Wegovy in Single-Dose Pen
Novo Nordisk (NVO) received a positive opinion from the European Medicines Agency's expert panel regarding its higher-dose version of Wegovy, an obesity therapy. The approval allows use of a single-dose pen containing 7.2 mg of the drug in Europe.
Tickers: $NVO
Topics: European Medicines Agency (EMA) obesity treatment pharmaceuticals Wegovy